Annual Cash & Cash Equivalents
$76.33 M
-$32.77 M-30.04%
December 31, 2023
Summary
- As of February 8, 2025, SPRO annual cash & cash equivalents is $76.33 million, with the most recent change of -$32.77 million (-30.04%) on December 31, 2023.
- During the last 3 years, SPRO annual cash & cash equivalents has fallen by -$8.88 million (-10.42%).
- SPRO annual cash & cash equivalents is now -32.20% below its all-time high of $112.58 million, reached on December 31, 2021.
Performance
SPRO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$76.29 M
+$12.76 M+20.09%
September 30, 2024
Summary
- As of February 8, 2025, SPRO quarterly cash and cash equivalents is $76.29 million, with the most recent change of +$12.76 million (+20.09%) on September 30, 2024.
- Over the past year, SPRO quarterly cash and cash equivalents has dropped by -$43.00 thousand (-0.06%).
- SPRO quarterly cash and cash equivalents is now -39.09% below its all-time high of $125.24 million, reached on September 30, 2020.
Performance
SPRO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SPRO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -30.0% | -0.1% |
| 3 y3 years | -10.4% | -0.1% |
| 5 y5 years | +124.0% | -0.1% |
SPRO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -32.2% | at low | -32.2% | +68.0% |
| 5 y | 5-year | -32.2% | +156.8% | -39.1% | +156.6% |
| alltime | all time | -32.2% | +1241.3% | -39.1% | +639.6% |
Spero Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $76.29 M(+20.1%) |
| Jun 2024 | - | $63.53 M(-22.8%) |
| Mar 2024 | - | $82.27 M(+7.8%) |
| Dec 2023 | $76.33 M(-30.0%) | $76.33 M(-18.6%) |
| Sep 2023 | - | $93.83 M(+20.8%) |
| Jun 2023 | - | $77.69 M(-19.3%) |
| Mar 2023 | - | $96.25 M(-11.8%) |
| Dec 2022 | $109.11 M(-3.1%) | $109.11 M(+116.3%) |
| Sep 2022 | - | $50.45 M(+11.1%) |
| Jun 2022 | - | $45.40 M(-37.0%) |
| Mar 2022 | - | $72.11 M(-35.9%) |
| Dec 2021 | $112.58 M(+32.1%) | $112.58 M(-0.2%) |
| Sep 2021 | - | $112.86 M(+57.7%) |
| Jun 2021 | - | $71.56 M(-7.1%) |
| Mar 2021 | - | $77.04 M(-9.6%) |
| Dec 2020 | $85.21 M | $85.21 M(-32.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | $125.24 M(+91.7%) |
| Jun 2020 | - | $65.34 M(+1.5%) |
| Mar 2020 | - | $64.36 M(+116.5%) |
| Dec 2019 | $29.73 M(-12.8%) | $29.73 M(-34.8%) |
| Sep 2019 | - | $45.60 M(-35.9%) |
| Jun 2019 | - | $71.13 M(+44.0%) |
| Mar 2019 | - | $49.40 M(+44.9%) |
| Dec 2018 | $34.08 M(-61.0%) | $34.08 M(-15.8%) |
| Sep 2018 | - | $40.48 M(-16.9%) |
| Jun 2018 | - | $48.72 M(-7.3%) |
| Mar 2018 | - | $52.55 M(-39.8%) |
| Dec 2017 | $87.29 M(+746.2%) | $87.29 M(+244.0%) |
| Sep 2017 | - | $25.37 M(-30.1%) |
| Jun 2017 | - | $36.30 M(+251.9%) |
| Dec 2016 | $10.31 M(+81.3%) | $10.31 M |
| Dec 2015 | $5.69 M | - |
FAQ
- What is Spero Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Spero Therapeutics?
- What is Spero Therapeutics annual cash & cash equivalents year-on-year change?
- What is Spero Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Spero Therapeutics?
- What is Spero Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Spero Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SPRO is $76.33 M
What is the all time high annual cash & cash equivalents for Spero Therapeutics?
Spero Therapeutics all-time high annual cash & cash equivalents is $112.58 M
What is Spero Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SPRO annual cash & cash equivalents has changed by -$32.77 M (-30.04%)
What is Spero Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SPRO is $76.29 M
What is the all time high quarterly cash and cash equivalents for Spero Therapeutics?
Spero Therapeutics all-time high quarterly cash and cash equivalents is $125.24 M
What is Spero Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SPRO quarterly cash and cash equivalents has changed by -$43.00 K (-0.06%)